MarketBeat
11 Nov 2026, 10:12 UTC · 6h ago
Impact · against what's priced in
DFTX is positively impacted by the concrete timeline for its DT120 FDA filing in H1 2027 and the expansion of its pipeline into PTSD. While early autism data is promising, the tiny sample size limits its immediate impact on valuation.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Definium Therapeutics plans to submit a new drug application for DT120 in the first half of 2027.
Newpublished 2026-11-11
So whatSubmission in H1 2027 sets the stage for a potential FDA decision by H2 2027 or early 2028.
More positive than 99% of claims this week
Definium reported positive early-signals-of-efficacy for DT402 in an open-label study of five participants with autism.
Continue reading
5 related stories
The confirmation of a H1 2027 FDA filing for DT120 after three positive Phase 3 studies provides a concrete catalyst for commercialization. Additionally, the intent to enter PTSD trials expands the long-term pipeline, though the DT402 autism data remains too preliminary to materially shift estimates.
Read from the article alone
Scored by the NIS engine · methodology.
Priced inarticle says 'recently reported'
So whatThe sample size of 5 is too small to shift EPS estimates, but validates the R-enantiomer approach for Phase 2a.
More positive than 76% of claims this week
The company may proceed with a GAD-only application if the FDA requires an additional MDD study before submission.
Newpublished 2026-11-11
More negative than 75% of claims this week
Definium plans to initiate a study for post-traumatic stress disorder next year.
Newpublished 2026-11-11
So whatExpanding into PTSD increases the long-term pipeline value but adds R&D spend in FY2027.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
Positive Phase 3 results for DT120 and promising early signals for DT402 provide strong clinical tailwinds.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
22h ago
−0.2%
Price flat so far
$34.56 vs $34.64 close before publication (Nov 10) · not market-adjusted
DFTX chart →
